Clinical trial NCT03564288: Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)
Official title: A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Lead sponsor: Oscotec Inc.
Sponsor class: INDUSTRY
Collaborators: name: PPD Development, LP
First posted: 2018-06-20
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This Phase I study is designed to assess the safety, tolerability, pharmacokinetics and anti-tumor effect of increasing doses of study drug SKI-G-801 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are unresponsive to currently available therapies. Eligible participants will receive cycles of treatment involving IV infusion of SKI-G-801 daily for 14 days followed by 14 days off. Treatment cycles will be repeated until progressive disease or unacceptable toxicity.


Eligibility criteria: Inclusion Criteria:

* Willing and able to provide written informed consent for participation, prior to completing any study-related procedures.
* Diagnosis of Acute Myeloid Leukemia (AML)
* Patients must have been off previous antileukemia therapy for at least 2 weeks or 5 half-lives, whichever is longer if the immediate prior regimen included only weekly chemotherapy; or 4 weeks or 5 half-lives, whichever is longer, from any therapy with therapeutic biologics and from any type of investigational therapy. Daily hydroxyurea for up to 2 weeks to keep the absolute blast count below 50 x 10⁹/L will be allowed, but must be discontinued 24 hours prior to administration of study drug. Hydroxyurea will be permitted during the first cycle of treatment if necessary.
* At least one prior induction regimen (with or without consolidation) which may have included hematopoietic stem cell transplantation (HSCT).
* Have adequate liver function.
* Have adequate renal (kidney) function.
* Female patients must either be of non-childbearing potential, or, if of childbearing potential, have a negative urine pregnancy test at screening and agree not to try to become pregnant during the study and for 45 days after the final study drug administration. Women of childbearing potential, if heterosexually active, must agree to use 2 forms of highly effective birth control as determined by the protocol, starting at screening, throughout the study period and for 45 days after the final study drug administration.
* Female patients must agree not to breastfeed at screening, throughout the study period and for 45 days after the final study drug administration.
* Male patients with female spouse/partner of childbearing potential, must agree to use 2 forms of highly effective birth control as determined by the protocol, starting at screening, throughout the study period and for 45 days after the final study drug administration.

Exclusion Criteria:

* Patient has a diagnosis of Acute Promyelocytic Leukemia (APL) or chronic myelogenous leukemia in blast crisis.
* If patient is post allogenic transplant and requires therapy for graft vs host disease (GVHD) within 14 days prior to date of screening.
* Requires treatment with concomitant drugs that prolong QT/QTc interval.
* Recent history of cardiac ischemic disease (acute myocardial infarction within 6 months; uncontrolled angina); severe uncontrolled ventricular arrhythmia; recent transient ischemic attack or stroke within 6 months of screening; poorly controlled hypertension (systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg).
* Patient has active, untreated central nervous system (CNS) disease.

Other protocol defined inclusion/exclusion criteria could apply.

Primary outcomes:
measure: Recommended phase 2 dose (RP2D)
timeFrame: From Cycle 1, Day 1 until disease progression, unacceptable toxicity, patient withdrawal from study, or judged not to be in patient's interest to continue in study, assessed up to 36 months
measure: Patients in complete remission or showing partial response (overall response rate [ORR])
timeFrame: Up to 30 days following last dose of study drug
measure: Patients in complete remission
timeFrame: Day 84 (± 3 days)
measure: Duration of remission
timeFrame: From date of first reported status of CR to the date of disease relapse or death (+ 1 day); or to date of last available disease status report for patients who do not relapse, assessed up to 36 months
measure: Duration of event free survival
timeFrame: Day 1 to date of event (first documented treatment failure, relapse from CR or Cri [CR with incomplete hematologic recovery], or death due to any cause), assessed up to 36 months
measure: Time to treatment response (TTR)
timeFrame: Day 1 to date of first subsequent disease status of CR (+ 1 day), assessed up to 36 months
measure: Dose limiting toxicity (DLT) Adverse Events (AEs)
timeFrame: Up to Day 28
Secondary outcomes:
measure: Incidence of Adverse Events (AEs)
timeFrame: Up to 30 days following last dose of study drug
measure: Number of participants with clinical laboratory abnormalities
timeFrame: Up to 30 days following last dose of study drug
measure: Number of participants with overall safety profiles
timeFrame: Up to 30 days following last dose of study drug
measure: Number of participants with electrocardiogram (ECG) abnormalities
timeFrame: Up to 30 days following last dose of study drug
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC Norris Comprehensive Cancer Center, Clinical Investigations Support Office (CISO), 1441 Eastlake Ave., Rm. 7327
state: California
city: Whittier
country: United States
facility: Innovative Clinical Research Institute
state: California
Study officials:
affiliation: Roswell Park Cancer Institute
name: Eunice Wang, MD
role: PRINCIPAL_INVESTIGATOR
References: